Friday, March 17, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Antimicrobial Resistance

Tru-D SmartUVC Locks in Disinfection Robot Agreement with HealthTrust

by Global Biodefense Staff
March 23, 2015

Tru-D SmartUVC LLC has announced an agreement with HealthTrust, which serves 1,350 acute care facilities and members in more than 15,000 locations.

Tru-D SmartUVC is a germ-eliminating UV disinfection robot used to kill germs and pathogens that plague health care environments. The device measures UVC dose and calculates the proper time needed to thoroughly deliver a measured dose of UV light from a single placement in the room.

The new agreement will allow Tru-D SmartUVC’s automated disinfection robot to be purchased and utilized by hospitals in the HealthTrust members that are committed to taking their infection prevention efforts to the next level.

“Hospitals are increasingly recognizing the need for an advanced and integrated approach to improving patient outcomes on several levels,” said Chuck Dunn, president and chief executive officer of Tru-D Smart UVC LLC. “Antibiotic resistant bacteria and HAIs are a challenge that cost health care facilities billions of dollars every year. By integrating advanced technology that has been proven as a solution time and time again, hospitals are not only saving money, but they are also protecting patients and staff from acquiring potentially deadly illnesses.”

HealthTrust members include acute, ambulatory surgery centers, physician practices, long-term care facilities and alternate care sites. With an established reputation in acute care facilities across the United States, Tru-D SmartUVC is now expanding access to other health care providers and facilities in the industry through this contractual partnership.

Third Party comparisons to pulsed xenon methods conclude Tru-D SmartUVC is six times more effective eliminating Clostridium difficile spores, seven times more effective removing vancomycin-resistant Enterococcus (VRE), and twice as effective against methicillin-resistant Staphylococcus aureus (MRSA).

Hundreds of Tru-Ds have been deployed to disinfect hospitals across the U.S., Canada, Europe and Africa, including the National Institutes of Health Clinical Center in Bethesda, Maryland; Nottingham University Hospitals NHS Trust’s QMC campus in Nottingham, England; and Ebola Treatment Units at ELWA Hospital and Island Hospital in Monrovia, Liberia.

Source: Tru-D SmartUVC press release, adapted.

Tags: C. diffMRSA

Related Posts

small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
DoD Awards ENA Respiratory $4.38M for Broad-Spectrum Antiviral Development
Industry News

DoD Awards ENA Respiratory $4.38M for Broad-Spectrum Antiviral Development

January 10, 2023
Killing Anthrax More Quickly with Hot Air Decontamination
CBRNE

Killing Anthrax More Quickly with Hot Air Decontamination

January 4, 2023
Bavarian Nordic to Supply Additional Monkeypox Vaccine to EU Member States
Industry News

Bavarian Nordic to Supply Additional Monkeypox Vaccine to EU Member States

September 7, 2022
Load More

Latest News

Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC